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Abstract
Background: In the last ten years, bioterrorism has become a serious threat and challenge to public health worldwide.
Pulmonary anthrax caused by airborne Bacillus anthracis spores is a life- threatening disease often refractory to antimicrobial
therapy. Inhaled spores germinate into vegetative forms that elaborate an anti-phagocytic capsule along with potent
exotoxins which disrupt the signaling pathways governing the innate and adaptive immune responses and cause
endothelial cell dysfunction leading to vascular injury in the lung, hypoxia, hemorrhage, and death.
Methods/Principal Findings: Using a murine model of pulmonary anthrax disease, we showed that a nuclear transport
modifier restored markers of the innate immune response in spore-infected animals. An 8-day protocol of single-dose
ciprofloxacin had no significant effect on mortality (4% survival) of A/J mice lethally infected with B. anthracis Sterne.
Strikingly, mice were much more likely to survive infection (52% survival) when treated with ciprofloxacin and a cell-
penetrating peptide modifier of host nuclear transport, termed cSN50. In B. anthracis-infected animals treated with
antibiotic alone, we detected a muted innate immune response manifested by cytokines, tumor necrosis factor alpha
(TNFa), interleukin (IL)-6, and chemokine monocyte chemoattractant protein-1 (MCP-1), while the hypoxia biomarker,
erythropoietin (EPO), was greatly elevated. In contrast, cSN50-treated mice receiving ciprofloxacin demonstrated a restored
innate immune responsiveness and reduced EPO level. Consistent with this improvement of innate immunity response and
suppression of hypoxia biomarker, surviving mice in the combination treatment group displayed minimal histopathologic
signs of vascular injury and a marked reduction of anthrax bacilli in the lungs.
Conclusions: We demonstrate, for the first time, that regulating nuclear transport with a cell-penetrating modifier provides
a cytoprotective effect, which enables the host’s immune system to reduce its susceptibility to lethal B. anthracis infection.
Thus, by combining a nuclear transport modifier with antimicrobial therapy we offer a novel adjunctive measure to control
florid pulmonary anthrax disease.
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Introduction
Pulmonary anthrax caused by inhaling B. anthracis spores
represents a serious threat in biowarfare and bioterrorism. This
threat is underscored by the accidental Sverdlovsk airborne
outbreak in the former Soviet Union and more recent attempts
to deliberately spread B. anthracis spores via the U.S. Postal Service
in 2001 [1,2]. Inhaled B. anthracis spores are disseminated
throughout the body causing bacteremia, which is refractory to
treatment with antibiotics and leads to extensive lung injury and
death [3]. The cardinal features of lung injury involve hemorrhage
in the mediastinum and pleural cavity, necrosis of mediastinal
lymph nodes, and pulmonary edema with hyaline membrane
formation. These life-threatening changes are due to the action of
toxins secreted from vegetative forms of the bacilli. Two toxic
effector proteins produced by bacilli, edema factor (EF) and lethal
factor (LF), each form a binary complex with a pore-forming
protective antigen (PA) [4].
The B. anthracis capsule and other conserved pathogen-
associated molecular structures are recognized by Toll-Like
Receptors (TLRs), the mainstays of innate immunity, initiating
signaling pathways that determine the immune system response to
bacterial infection [5]. Dendritic cells, which normally play a key
role in this response to prevent the spread of anthrax bacteria from
the site of infection throughout the body [6], are ‘‘disarmed’’ by
LF and EF [7–9]. These toxic enzymes profoundly alter innate
and adaptive immune responses that enable production of TNFa
and other pro- and anti-inflammatory cytokines needed to fight
infection [10]. Edema factor acts as a calcium- and calmodulin
(CaM)-dependent adenylate cyclase that is 1,000 fold more active
than mammalian CaM-activated adenylate cyclase [11–13]. It
causes prominent edema at the site of infection, the inhibition of
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and IL-6 by monocytes [14,15]. EF-generated cAMP activates
cAMP-dependent protein kinase A (PKA), which in turn
phosphorylates cAMP response element binding protein (CREB)
[14,16] leading to suppression of mitogen-activated protein
kinase (MAPK) kinase p38 [17] and inhibition of multiple
transcription factors involved in cytokine production such as
nuclear factor kappa B (NFkB) [18] and nuclear factor of
activated T cells (NFAT) [19]. Lethal factor, a zinc metallopro-
tease, suppresses production of two effectors of innate immunity
in macrophages, TNFa, and nitric oxide (NO), and reduces
expression of other cytokine gene transcripts [20–22]. LF also
inactivates MAPK kinase, leading to aberrant intracellular
signaling [15] and contributing to the death of cultured
macrophages [23–26]. Thus, anthrax toxins greatly affect the
signaling to the nucleus essential for genome reprogramming in
macrophages and dendritic cells.
Transcription factors are transported to the nucleus by the
adaptors importins/karyopherins [10,27]. These adaptors rec-
ognize the nuclear localization signal (NLS) on karyophilic
proteins and thereby transport an array of signal transducers and
transcription factors across the nuclear membrane [28]. Their
‘‘cargos’’ include, among others, NFkB, activator protein 1 (AP-
1), CREB, and interferon regulatory factor 3 (IRF3) [29].
Previously, we demonstrated in a murine model of lethal shock
induced with bacterial endotoxin that survival was increased
from 0% to 90% by treatment with a cell-penetrating nuclear
transport modifier [30]. Therefore, we postulated that modulat-
ing the nuclear shuttling of these and other transcriptional
activators and repressors of innate and adaptive immunity might
provide in vivo protection from overwhelming infection with B.
anthracis spores.
To test the hypothesis that a nuclear transport modifier would
display a protective effect in pulmonary anthrax, we selected a
treatment protocol in which pulmonary anthrax was caused by a
lethal dose of inhaled B. anthracis spores refractory to an 8-day
treatment with the antibiotic ciprofloxacin. The cSN50 peptide
employed in this model contains a cyclized form of the NLS from
the p50/NFkB1 subunit of NFkB. The NLS was fused to the
signal sequence-derived hydrophobic region from fibroblast
growth factor 4. This hydrophobic segment serves as a
membrane-translocating motif (MTM), which enables peptide or
protein cargo to penetrate the plasma membrane of multiple cell
types in various organs through a receptor/transporter- and
endocytosis-independent mechanism [31–33]. NLS, as a cargo,
competitively targets the adaptor Rch1/importin alpha 1/
karyopherin alpha 2 [34], among other importins/karyopherins
(Zienkiewicz J., Armitage A., and Hawiger J. unpublished),
thereby modulating its nuclear shuttling function. We surmised
that regulating nuclear transport of the overexpressed repressors of
innate immunity generated by the high levels of cAMP induced by
LF would help restore normal immune function. Concurrently,
controlling nuclear transport of activators could prevent an
excessive inflammatory response.
We now show that cell-penetrating nuclear transport modifier,
cSN50, suppressed lung injury and lethality of pulmonary anthrax
when mice exposed to 10 million spores of B. anthracis Sterne were
also treated with the antibiotic ciprofloxacin. Adjunctive treatment
with cSN50 restored components of the innate immune response
and reduced levels of the hypoxia biomarker, erythropoietin
(EPO). Lung edema and hemorrhagic lesions were ameliorated
and survival was significantly increased. Thus, the addition of a
nuclear transport modifier in antibiotic–treated pulmonary
anthrax markedly reduced lethality in this model.
Results
We tested our hypothesis that abnormal signaling to the nucleus
is responsible for suppression of the innate immune response by
anthrax toxins. Therefore, we examined the effect of a cell-
penetrating peptide modifier of nuclear transport, cSN50, in an in
vivo model of pulmonary anthrax treated with the antibiotic
ciprofloxacin. To compensate for lower virulence of capsule –
deficient B. anthracis Sterne, we employed an experimental model
of pulmonary anthrax infection using A/J mice. These mice are
C5 complement protein-deficient, thus being susceptible to B.
anthracis infection with Sterne strain [35]. Consistent with prior
studies [36], this experimental model of pulmonary anthrax via
intranasal administration of B. anthracis spores was effective in
delivering up to 70% of infectious units to the lungs.
Because our pilot experiments using monotherapy with cSN50
peptide alone to treat spore-infected mice did not improve survival
but indicated a significant delay in time to death and a rise in serum
levels of the chemokine monocyte chemoattractant protein-1 (MCP-
1) (not shown), we designed a combination therapy by adding
ciprofloxacin to treatment with the nuclear transport modifier. We
chose a dosing schedule of ciprofloxacin that would partially control
the rapid replication of anthrax bacilli in infected animals but not
prevent the lethal outcome. Using a ciprofloxacin protocol that
favored the lethal outcome provided a sufficient system for
evaluating the impact of cSN50 peptide treatment on the course of
infection while controlling rapid replication of bacilli with antibiotic.
We evaluated the consequences of adjunctive treatment with a
nuclear transport modifier not only by survival but also by
monitoring the dynamic changes in mediators of innate immunity
(cytokines and chemokine) and the hypoxia biomarker EPO.
These mechanistic studies were complemented by histologic
examination of the extent of lung injury and involvement of other
organs. This analysis also allowed us to monitor the spread or
containment of B. anthracis toxin-producing vegetative forms.
Results of the experiments presented below establish the hitherto
unrecognized role of nuclear transport modifier in correcting
deranged innate immune and hypoxia responses in this model of
inhalational anthrax, thereby significantly increasing survival of
anthrax spore-infected animals.
Increased Survival of Mice Challenged with B. anthracis
Spores and Treated with Nuclear Transport Modifier
cSN50 and Ciprofloxacin
W tested a cell-penetrating nuclear transport modifier, cSN50
peptide, forits effect on survival ofB. anthracisspore-challenged mice
treated with ciprofloxacin. Each mouse was infected with 10
7 spores
and treated with multiple intraperitoneal (IP) injections of either
cSN50 or saline. Twenty four hours after exposure to spores, daily
administration of ciprofloxacin was begun and continued for 8 days.
We titrated the doses of spores and ciprofloxacin so that death was
delayed but not prevented. Untreated control mice were given IP
saline injections, butnociprofloxacin.These mice died between 2 to
4 days post-infection (Fig. 1), while 50–70% of the infectious spore
dose was recovered from the lungs of representative animals
sacrificed one hour post-infection. Prior to death, mice developed
laboredrespirations,mostlikelyduetolungandpleuralinjurynoted
at autopsy. Mice receiving ciprofloxacin and saline lived longer, but
ultimately all but one succumbed to infection within 9 days (4%
survival). In contrast, a significant number of mice receiving a
combination of nuclear transport modifier, cSN50, and ciproflox-
acin survived (Fig. 1). Survival at the ninth day in three independent
experiments was 52% (p,0.001). At that time point, survivors were
euthanized to evaluate the extent of lung injury. Four mice treated
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signs of recurrent B. anthracis infection. Thus, nuclear transport
modifier cSN50 enhanced the survival following suboptimal
antibiotic treatment of mice exposed to B. anthracis spores.
In Vivo Levels of Cytokines, Chemokine, and
Erythropoietin in B. anthracis- Infected Mice
Innate immune response to non-toxin-producing mutants of B.
anthracis is manifested by the production of proinflammatory
cytokines. In contrast, lung dendritic cells infected with toxin-
producing strains of B. anthracis display a striking paucity of
cytokine production reflecting suppression of the innate immune
response [6]. Consistent with these prior observations, mice
receiving saline only or saline and ciprofloxacin following B.
anthracis spore challenge showed depressed levels of TNFa, IL-6,
and MCP-1. Surprisingly, treatment with cSN50 and ciprofloxacin
restored induction of these mediators of innate immunity in B.
anthracis-infected animals (Fig. 2). Other pro- and anti-inflamma-
tory cytokines, IL-12p70, interferon gamma (IFNc), and IL-10
remained unchanged (not shown). Increased hypoxia, manifested
by an elevated level of its biomarker, erythropoietin (EPO), has
been previously reported in mice challenged with anthrax lethal
toxin [37]. Consistent with these prior findings, EPO was elevated
at 48 h after B. anthracis spore infection and at death in control
mice that received saline only or saline and ciprofloxacin. In
contrast, this hypoxia marker was attenuated in all mice receiving
treatment with cSN50 and ciprofloxacin (Fig. 2). Thus, nuclear
transport modifier suppressed hypoxia associated with the lethal
outcome of pulmonary anthrax.
Histologic Analysis of Head, Lungs and Other Organs in B.
anthracis-Infected Mice
There were no signs of infection in the sinuses or brain of
untreated control mice infected IN with B. anthracis, and very few
spores were detected in the sinus cavities of mice sacrificed one
hour after instillation, indicating that in this model infection is
primarily initiated by spores reaching the upper airways.
Untreated mice showed marked pulmonary edema (Fig. 3A–B),
hemorrhage (Fig. 3C) and clumps of B. anthracis bacilli were
prominent in lung tissue (Fig. 3D). There were also many B.
anthracis bacilli in the vessels of the heart, kidneys, spleen, and liver
indicating bacteremic spread of B. anthracis vegetative forms (not
shown) as observed in the victims of the bioterrorism-related
inhalational anthrax outbreak and in other animal studies. The
PAS staining in Fig. 3B showed the extent of edema. In the lungs
of mice receiving ciprofloxacin alone, foci of edema and
hemorrhage were found (Fig. 3E), along with clumps of B. anthracis
vegetative forms as shown with PAS stain in Fig. 3F. In contrast,
surviving mice treated with cSN50 peptide and ciprofloxacin
showed minimal pulmonary edema at the ninth day of observation
(Fig. 3G) and lungs were essentially normal in mice euthanized at
21 days (Fig. 3H). PAS-stained sections in mice from these groups
of survivors were negative for B. anthracis vegetative forms in all
organs examined, and very few spores were detected in lung
sections stained with a modified Ziehl’s carbol fuchsin dye for
spores in tissues (not shown). In mice that succumbed to infection,
there were fewer stained spores seen in lungs of cSN50-treated
animals compared to those treated with ciprofloxacin alone. Thus,
the cytoprotective effect of cSN50 peptide in the lungs correlated
with the survival of mice challenged with 10
7 B. anthracis spores
and receiving ciprofloxacin also. Moreover, the beneficial effect of
cSN50 peptide added to ciprofloxacin facilitated lung clearance of
B. anthracis bacilli and prevented their spread to other organs (the
heart, spleen, liver, and kidneys).
Discussion
These results show that a nuclear transport modifier restored
the markers of the innate immune response and prevented the
florid toxicity of pulmonary anthrax. While the once-daily dosing
schedule of ciprofloxacin used here can lead to development of
antibiotic-resistant organisms in as little as one day after infection
[38], this only accentuates the ability of cSN50 to potentiate the
innate immune system to limit the progression and lethal outcome
of pulmonary anthrax. However, ciprofloxacin, through its ability
to reduce anthrax biofitness by inducing error-prone replication at
the suboptimal dosage used in this model, may have acted in
synergy with cSN50 and thereby enhanced its apparent effect.
Whether this interaction is needed for the cSN50 effect and
whether nuclear transport modulation would be equally effective
in conjunction with alternative antibiotic treatments has not yet
been determined. Among the first 10 cases of bioterrorism-related
inhalational anthrax reported in the United States in 2001 survival
was 60% [39]. Those who succumbed were presenting fulminant
signs of illness when they were first treated with antibiotics directed
toward B. anthracis. Whether adjunctive therapy that restores
innate immunity and affords cytoprotection can attenuate
fulminant signs of illness in ultimately fatal cases remains to be
investigated.
Cell-penetrating nuclear transport modifier has a broad anti-
inflammatory and cytoprotective spectrum. In vivo cytoprotection
by cSN50 peptide has been previously demonstrated in endotoxic
lipopolysaccharide (LPS) and staphylococcal enterotoxin B (SEB)
models. These models are characterized by overproduction of
proinflammatory cytokines and chemokines in acute lung
inflammation as well as acute liver inflammation associated with
massive apoptosis and hemorrhagic necrosis [40–42]. Moreover,
Shiga toxin 2-induced endothelial cell injury was attenuated with
Figure 1. Survival in inhalational anthrax was increased by
combination of cSN50 with ciprofloxacin. Female A/J mice were
infected intranasally (IN) with 10
7 B. anthracis spores and treated with
15 injections of cSN50 during the first 2 days and daily ciprofloxacin
(triangles) or saline and ciprofloxacin (squares) or saline without
ciprofloxacin (circles). The p value represents the significance of the
difference in survival between the two ciprofloxacin-treated groups
(with and without cSN50 peptide).
doi:10.1371/journal.pone.0030527.g001
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that in mice treated with cSN50 peptide, expression of hundreds of
LPS-inducible and LPS-suppressed genes were modulated in the
liver and spleen (Li C., Liu XY., Sims L., Levy S., and Hawiger, J.
unpublished results). Thus, cSN50 peptide has a bimodal effect on
regulation of genes that encode mediators of innate immune
function depending on the cell type and the nature of the
microbial pathogen. In pulmonary anthrax, the unlocking effect of
cSN50 peptide on suppressed innate immunity mediators (TNFa,
IL6, and MCP-1) is consistent with bimodal regulation of genome-
wide response by this nuclear transport modifier.
The complex interplay of B. anthracis virulence factors incapac-
itates macrophages, dendritic cells, T cells, and natural killer T cells
[7,44,45]. Therefore our findings withcSN50 indicate its restorative
action on innate immune responses in anthrax toxin-deranged cells
by unlocking expression of TNFa, IL6, and MCP-1. These
mediators of innate immunity are regulated by CBP/p300;
therefore the exceedingly high levels of cyclic AMP generated by
EF [11–13] can dysregulate the activities of the CREB family of
basic leucine zipper transcription factors that act as both
transcriptional activators and repressors depending on the cell type
and stimulus [46]. A member of the CREB/ATF family, activating
transcription factor 3 (ATF3) is a negative regulator of genes that
encode proinflammatory cytokines IL-6 and IL-12 [47]. ATF3 was
transcriptionally upregulated in lethal toxin-challenged cultured
mouse macrophages [48]. Nuclear translocation of this and other
repressors of cytokine genes is required for their genome regulatory
activity [29]. Our previous studies have established the role of
cSN50 in regulating nuclear transport of stress-responsive tran-
scription factors NFkB, NFAT, AP-1, and STAT1 [10,34] while
unpublished results indicate that cSN50 is able to affect nuclear
trafficking of ATF3, hypoxia-induced factor 1 (HIF-1), IRF3 and
CREB as well (Veach RA. and Hawiger J. unpublished results).
In summary, we have demonstrated that a cell-penetrating
modifier of nuclear transport, cSN50 peptide, offers a promising
adjunctive therapy to the treatment of pulmonary anthrax. Given
its rapid delivery and therapeutic potential, this cell-penetrating
nuclear transport modifier may represent a more favorable
strategy for a combination treatment of systemic anthrax than
previously reported vaccine and monoclonal antibodies.
Materials and Methods
Ethics Statement
All animal handling and experimental procedures were
performed in accordance with the American Association of
Accreditation of Laboratory Animal Care guidelines and approved
by the Institutional Animal Care and Use Committee of
Vanderbilt University. The laboratory animal care program of
VU (PHS Assurance #A3227-01) has been accredited by
AAALAC International since 1967 (File #000020). Mice are
closely monitored to minimize the amount of pain experienced by
the animals, and those that exhibit end-stage symptoms are
euthanized as soon as it is apparent they will not recover.
Peptide Synthesis and Purification
MTM-containing peptide cSN50 was synthesized, purified,
filter-sterilized, and analyzed as described previously [30,34].
Figure 2. cSN50 restored depressed cytokine/chemokine responses to B. anthracis infection and attenuated a rise in erythropoietin,
a hypoxia biomarker. Blood serum levels of TNFa, IL-6, and MCP-1 were measured in female A/J mice infected with 10
7 B. anthracis spores IN and
treated with cSN50 and daily ciprofloxacin (solid squares) or saline and ciprofloxacin (solid triangles) or saline without ciprofloxacin (open triangles) as
in Fig. 1. Blood serum levels of Erythropoietin were measured in the same mice: cSN50 and ciprofloxacin (white), saline and ciprofloxacin (diagonal
lines) or saline without ciprofloxacin (black). Error bars indicate the+S.E. of the mean value in mice represented by each data point. The p values
represent the significance of the differences between the two ciprofloxacin-treated groups.
doi:10.1371/journal.pone.0030527.g002
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Bacillus anthracis Sterne strain was grown in 26SG medium
(nutrient broth supplemented with 2 mM Magnesium Sulfate,
27 mM Potassium Chloride, 1 mM Calcium Nitrate, 100 mM
Manganese Chloride, and 700 nM Ferrous Sulfate) at 37uC with
constant shaking (300 rpm) until sporulation (5–7 days). The
culture was centrifuged for 7 min at 8000 g at 4uC, resuspended in
sterile water, heated at 65uC for 1 h to kill vegetative bacilli and
germinated spores then washed 3 times with sterile water [49].
Phase microscopy confirmed that the resulting preparation
contained .95% refractile spores. The number of colony forming
units (cfu) was determined by plating serial dilutions of spores on
Luria broth (LB) agar and counting the B. anthracis colonies. Spores
were aliquoted in 20% glycerol and stored at 280uC. The number
of cfu was reconfirmed before each use.
Pulmonary Anthrax Model in Animals
Female A/J mice (7–8 weeks) were purchased from the Jackson
Laboratories (Bar Harbor, ME), and randomly assigned to study
groups. For B. anthracis Sterne spore instillation, mice were
anesthetized by intraperitoneal (IP) injection of 50 mg/kg
Nembutal, and 1610
7 spores in 50 ml saline were administered
to each mouse intranasally (IN). The number of spores reaching
the lungs was determined in each experiment. Briefly, 2–3 mice
were sacrificed 1 h post-infection and lungs were removed under
sterile conditions, homogenized, and serial dilutions of homoge-
nates plated on LB agar. By this method we determined that 50–
70% of the instilled dose of spores reached the lungs of infected
mice. Mice that received doses of 10
5 or 10
6 spores IN were
observed for 9 days and all were asymptomatic and survived (not
shown). In contrast, all mice that received 10
7 spores died within 4
days with signs of overt infection (see Results and Discussion).
Animal Treatment Protocol
Female A/J mice were injected IP with 200 ml saline or cSN50
peptide (3.5 mg/ml) at 30 minutes before and 30 minutes, 1.5 h,
2.5 h, 3.5 h, 6 h, 9 h, 12 h, 15 h, 18 h, 21 h, 24 h, 30 h, 36 h, and
42 h after IN infection with 10
7 spores of B. anthracis Sterne strain.
Treatment with ciprofloxacin, 50 mg/kg, was administered subcu-
taneously (s.c.),beginning 24 h after spore challenge and continuing
once daily for 8 days. Blood was collected from the saphenous vein
before infection, at 12, 24, 36 and 48 h after spore challenge, and at
death. Serum was separated from clotted blood and stored at
220uC. All animals were observed for morbidity and mortality for
up to 9 days and some cSN50 peptide-treated mice were monitored
for up to 21 days after spore challenge. Moribund animals were
humanely euthanized by IP injection of pentobarbital. Surviving
animals were euthanized in the same manner 9 or 21 days after
spore challenge. Organs and heads of mice were collected at death
and immersed in 10% formalin for histologic analysis (see below).
Cytokines, Chemokine, and Erythropoietin Assays in
Serum
We measured IL-6, TNFa, IFNc, IL-10, IL-12, and MCP-1 in
serum by a Cytometric Bead Array according to the manufactur-
er’s instructions (BD Biosciences). Murine erythropoietin (EPO)
was measured by enzyme-linked immunosorbent assay (ELISA)
according to the manufacturer’s instructions (R and D Systems).
Results are expressed as the mean+S.E.
Histological Analyses
Organ samples (lungs, liver, spleen, heart, and kidney) and
heads (skin removed) were collected at death from mice who
succumbed to B. anthracis infection and from surviving mice
euthanized after 9 or 21 days. Formalin-fixed, paraffin-embedded
sections were stained with hematoxylin and eosin (HE) or periodic
acid-Schiff and hematoxylin (PAS) to assess damage from infection
and presence of B. anthracis vegetative forms, and with a modified
Ziehl-Neelson dye, using hot carbol fuchsin at 60 degrees for
4 minutes followed with a methylene blue counterstain, to detect
spores in tissues [50,51].
Statistical Analyses
A log rank test was used for statistical analysis of survival. A one-
way analysis of variance, a two-way repeated measure analysis of
variance and the Student’s t test were used to determine the
significance of the difference in the levels of cytokines, chemokine,
and erythropoietin.
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